Streamlining and harmonising the global drug development pathway for Alzheimer's disease treatment
26 May 2016, SwissTech Convention Center, Lausanne, Switzerland
Website: thebrainforum.org
Dr. Antonella Chadha Santuccione from the Swiss Agency for Therapeutic Products gives a regulator’s view on how (besides a fast-track line), an early dialogue with Authorities, combined with adequate, and agreed upon preclinical work and measures to ensure the safety and interest of the patient, is the best way forward to cut the drug development time and save costs.
About speaker
Dr. Antonella Santuccione Chadha joined the Swiss Agency for Therapeutic Products in Bern in 2014 as a Specialised Clinical Reviewer in the field of psychiatric disorders. Previous to this, she was appointed by Roche as Medical Manager for Psychiatry. Before joining the industry, she worked as a neuroscientist and a medical doctor at the Psychiatry University Hospital in Zurich.
During this period she extensively investigated the pathogenesis of Alzheimer’s disease (AD) and other neurodegenerative disorders. The focus of her studies was to identify a possible immunotherapy for AD.
About The Brain Forum
Researchers, engineers, healthcare professionals, entrepreneurs, industrialists, investors, funding agencies and policy makers meet at The Brain Forum 2016, to advance our understanding of how the brain works and to accelerate the application of this knowledge in society and the economy.